Introduction {#s1}
============

Socioeconomic status (SES) has a broad impact on health outcomes and longevity and encompasses a variety of factors including income, education, occupation, race and social status. Lower incomes are specifically associated with reduced life expectancy, although the effect varies across geographic regions \[[@C1]\]. The reduction in life expectancy associated with low income is significantly influenced by regional differences in health behaviours, especially smoking \[[@C1]\]. Race and sex, which are strongly associated with SES, have been identified as risk factors for more severe chronic obstructive pulmonary disease (COPD) \[[@C2]--[@C5]\]. COPD is linked to smoking and other respiratory exposures such as gases, smoke, fumes and dust commonly found in low-income jobs. Earlier published works regarding impacts of low income and SES focused on symptoms \[[@C6], [@C7]\], disease severity \[[@C6]\], racial disparities \[[@C8], [@C9]\] and COPD within a general population cohort \[[@C10]\]. However, the effect of low income as a factor in disease progression has not been assessed comprehensively.

The COPDGene study enrolled 10 192 smokers with and without COPD (phase 1) and characterised them with spirometry, chest computed tomography (CT) scans and symptoms. Subjects returned for a 5-year follow-up visit (phase 2) to assess disease progression by repeat spirometry, CT imaging and reported symptoms. During the phase 2 visit they provided information on their current annual income, insurance status and access to medications and health care.

We assumed income stability over the 5-year interval and postulated that the lowest income subjects (earning \<USD 15 000 USD per year) would have worse respiratory symptoms and decreased quality of life. We also hypothesised that low income would be associated with worse outcomes over 5 years, specifically increasing spirometric obstruction and progression of pulmonary disease on CT scans.

Methods {#s2}
=======

Study population {#s2a}
----------------

COPDGene (Genetic Epidemiology of COPD) is a longitudinal cohort study at 21 clinical centres across the United States. Subjects were current and former smokers aged 45--80 years at entry, non-Hispanic white or African American subjects who reported smoking histories \>10 pack-years and had no other lung disease except asthma \[[@C9]\]. All subjects provided documentation of informed consent in writing and the study was approved at each clinical centre by their local institutional review board. Details of the phase 1 study have been presented previously \[[@C9]\]. In phase 2 of the study during the years 2013--2017, subjects completed a 5-year return visit. At this second visit, subjects had a comprehensive examination including repeat spirometry, a 6-min walk test, questionnaires and a CT scan. Subjects included in this analysis are those who completed an in-person phase 2 visit, passed spirometry quality control at both visits and reported income during the phase 2 visit (see [figure 1](#F1){ref-type="fig"} for CONSORT diagram).

![COPDGene consort diagram.](00069-2018.01){#F1}

The low-income group in our analysis was defined as participants earning less than the United States federal minimum wage of USD 7.25 per hour. A person earning minimum wage working 40 h per week, 52 weeks per year (just over full time) would earn USD 15 080 before taxes. Any participant who reported earning more than USD 15 000 per year was categorised as higher income.

Aims {#s2b}
----

Our primary aim was to assess the role of low income as a predictor of disease progression for subjects with COPD and early smoking-related lung disease after correcting for the possible confounding variables of age, sex, race, current smoking, education, baseline function and pack-years. Disease progression variables included change in percentage emphysema, change in FEV~1~ and change in gas trapping over a 5-year time period. Our secondary aim was to investigate the relationship of income to baseline patient variables including symptoms, spirometry and CT-based estimates of emphysema severity, airway wall thickness and gas trapping.

Questionnaires {#s2c}
--------------

Questionnaires in phase 1 included medical history, educational history, a modified American Thoracic Society respiratory questionnaire, the modified Medical Research Council (mMRC) dyspnoea score \[[@C11]\], St George\'s Respiratory Questionnaire (SGRQ) \[[@C12]\] and the Medical Outcomes Study 36-item short form survey (SF-36) \[[@C13]\]. In phase 2, the COPD Assessment Test (CAT) and a socioeconomic questionnaire were added. The socioeconomic questionnaire queried annual income, insurance status, home ownership and access to preventative care. Education was considered as a categorical variable, with high school or less *versus* any education beyond high school. Comorbid disease was self-reported on the medical history questionnaire. We calculated a nonweighted comorbidity score using the methodology of P[utcha]{.smallcaps} *et al.* \[[@C14]\], summing the number of comorbidities.

Functional evaluations {#s2d}
----------------------

Function was evaluated using post-bronchodilator spirometry to determine forced expiratory volume in 1 s (FEV~1~), forced vital capacity and 6-min walking distance (6MWD).

Radiographic measures {#s2e}
---------------------

Inspiratory and expiratory CT scans were performed on all participants who consented. Details of the lung CT protocol and quantitative analysis have been reported elsewhere \[[@C15]\]. Inspiratory CT scans were analysed for emphysema as percentage low attenuation area at −950 Hounsfield Units (%LAA@-950HU) and adjusted lung density as well as for airway wall thickness. Expiratory CT scans were analysed for gas trapping using percentage low attenuation area at −856 Hounsfield Units (%LAA@-856HU). All CT scans were analysed using Thirona LungQ (Thirona, Nijmegen, the Netherlands).

Statistical analysis {#s2f}
--------------------

Data were analysed using STATA 15.1 (StataCorp, College Station, TX, USA). Phase 1 to phase 2 changes were calculated for FEV~1~, mMRC dyspnoea score, SGRQ total score and distance walked. The percentage emphysema, adjusted lung density, gas-trapping scores and airway wall thickness at phase 1 and phase 2 were used to calculate the 5-year difference in CT variables. Comparisons between groups with categorical variables were made using a Chi-squared test and continuous variables were compared with a two-tailed t-test. p-values \<0.05 were considered significant. Multivariate linear regression was used to assess the independent effects of income and education on 1) baseline imaging measures of emphysema, gas trapping and airway wall thickness and 2) the 5-year change variables: FEV~1~ % predicted, emphysema, gas trapping and airway wall thickness. Baseline models were fitted with age, race, sex, current smoking status, smoking pack-years, education and income; while change models added the baseline value of the change modelled (either FEV~1~ % pred, emphysema, gas trapping or airway wall thickness). Statistically different demographic variables ([table 1](#TB1){ref-type="table"}) and clinically significant variables were selected *a priori* for regression models.

###### 

Demographics and baseline disease severity

                                                 **Low-income smokers (\<USD** **15** **000 per year)**   **Higher-income smokers (\>USD** **15** **000 per year)**   **p-value**
  --------------------------------------------- -------------------------------------------------------- ----------------------------------------------------------- -------------
  **Subjects n**                                                          1549                                                      3277                             
  **Age years**                                                         55.7±7.4                                                  61.7±8.5)                            \<0.0001
  **African American**                                                     57                                                        16                                \<0.0001
  **Male**                                                                 49                                                        52                                  0.031
  **BMI kg·m**^−2^                                                      29.1±6.7                                                  29.1±5.7                               0.95
  **More than high-school education**                                      45                                                        77                                \<0.0001
  **ATS pack-years**                                                   42.5±25.0                                                  42.2±22.6                              0.66
  **Age started smoking years**                                         16.7±5.1                                                  17.2±4.1                              0.0016
  **Current smoking status**                                               73                                                        36                                \<0.0001
  **Using respiratory medications**                                        42                                                        31                                \<0.0001
  **FEV**~**1**~ **% pred**                                            78.4±23.2                                                  80.4±23.0                             0.0042
  **FVC % pred**                                                       87.7±17.8                                                  89.6±16.5                             0.0002
  **FEV**~**1**~**/FVC**                                               0.70±0.14                                                  0.68±0.14                             0.0003
  **Percentage emphysema LAA@-950** **HU**                              4.68±7.6                                                  6.24±8.9                             \<0.0001
  **Percentage gas trapping LAA@-856** **HU**                          19.3±17.9                                                  20.5±17.8                             0.0652
  **Airway wall thickness mm**                                        1.063±0.231                                                1.018±0.211                           \<0.0001

Data are presented as mean±[sd]{.smallcaps} or %, unless otherwise stated. BMI: body mass index; ATS: American Thoracic Society; FEV~1~: forced expiratory volume in 1 s; FVC: forced vital capacity; LAA: low-attenuation areas.

Results {#s3}
=======

Demographics {#s3a}
------------

4826 subjects self-reported annual income and other information about their socioeconomic situation. Of the full cohort, 1549 (32%) subjects reported an income of \<USD 15 000 per year. The low-income participants were on average younger (55.7±7.4 years *versus* 61.7±8.5 years, p\<0.0001), more likely to be current smokers (72.6% *versus* 35.5%, p\<0.0001), had started smoking at an earlier age (16.7±5.1 years *versus* 17.2±4.1 years, p=0.0016), more likely to be using respiratory medications (42% *versus* 31%, p\<0.0001) and were more likely to be African American (57% *versus* 16%, p\<0.0001) ([table 1](#TB1){ref-type="table"}). The two groups had similar smoking exposure (42.7±25.1 pack-years *versus* 42.6±22.7 pack-years, p=0.8828) at baseline. Spirometric disease severity was slightly worse in the low-income participants with mean FEV~1~ 78.4±23.2% pred compared to 80.4±23.0% pred in the higher-income group (p=0.0042). Distribution by Global Initiative for Chronic Obstructive Lung Disease (GOLD) stage was similar between the two groups ([figure 2](#F2){ref-type="fig"}) with increased prevalence of preserved ratio impaired spirometry (PRISm) subjects in the low-income group and a small increase of GOLD stage 1 in the higher income group \[[@C16]\].

![Income status by Global Initiative for Chronic Obstructive Lung Disease (GOLD) stage. Higher- and low-income status was identified for phase 2 subjects who reported annual income based on income \>USD 15 000 (higher) and \<USD 15 000 (low). Percentage of subjects in higher- and low-income categories is shown for each GOLD stage. In general, the distribution of income status is similar across the GOLD stages except for an excess of low-income subjects in the preserved ratio impaired spirometry group and fewer in GOLD stage 1.](00069-2018.02){#F2}

Symptoms, comorbid disease and quality of life {#s3b}
----------------------------------------------

Symptoms were reported in both the phase 1 and phase 2 visits ([table 2](#TB2){ref-type="table"}). Low-income subjects had significantly more symptoms (chronic bronchitis 22% *versus* 14%, severe exacerbations 13% *versus* 7%, mMRC dyspnoea score ≥2 49% *versus* 28%) in phase 1 with similar results in phase 2. Low-income subjects scored higher (worse) on the CAT in phase 2, with a mean±[sd]{.smallcaps} score of 15.0±9.2, compared to 10.5±7.7 for higher-income subjects. Self-report of diabetes, congestive heart failure and stroke were significantly higher at baseline in the low-income group, while cancer, osteoarthritis, high cholesterol, hay fever and gastro-oesophageal reflux disease were significantly lower. Coronary artery disease, obesity, stomach ulcers, peripheral vascular disease, sleep apnoea and hypertension were not significantly different between groups. The overall comorbidity score was significantly lower in the low income group ([online supplementary table S1](http://openres.ersjournals.com/lookup/doi/10.1183/23120541.00069-2018.figures-only#fig-data-supplementary-materials)). The low-income group had a mean SGRQ total score of 31.7±23.3 *versus* 19.3±18.8 in phase 1 and 31.8±23.16 *versus* 19.6±19.0 when assessed at their phase 2 visit, with higher SGRQ score indicating lower quality of life. Both the mental and physical component scores of the SF-36 were significantly lower (worse) in the low-income group at both time points.

###### 

Symptoms, function and quality of life

                                               **Low-income smokers (\<USD** **15** **000 per year)**   **Higher-income smokers (\>USD** **15** **000 per year)**   **p-value**
  ------------------------------------------- -------------------------------------------------------- ----------------------------------------------------------- -------------
  **Phase 1**                                                                                                                                                      
   Chronic bronchitis                                                    22                                                        14                                \<0.0001
   mMRC score                                                        1.58±1.46                                                  0.93±1.24                            \<0.0001
   mMRC score \>2                                                        49                                                        28                                \<0.0001
   Severe exacerbation within the past year                              13                                                         7                                \<0.0001
   SGRQ total                                                        31.74±23.3                                                 19.3±18.8                            \<0.0001
   6MWD feet                                                          1297±381                                                  1486±352                             \<0.0001
   SF-36 PCS                                                         42.0±11.2                                                  47.1±10.0                            \<0.0001
   SF-36 MCS                                                         45.95±12.6                                                 52.4±9.8                             \<0.0001
  **Phase 2**                                                                                                                                                      
   Chronic bronchitis                                                    20                                                        13                                \<0.0001
   mMRC                                                              1.64±1.51                                                  0.99±1.29                            \<0.0001
   mMRC score \>2                                                        52                                                        31                                \<0.0001
   Severe exacerbation within the past year                              14                                                         7                                \<0.0001
   SGRQ total                                                        31.79±23.1                                                 19.6±19.0                            \<0.0001
   6MWD feet                                                          1168±438                                                  1356±420                             \<0.0001
   SF-36 PCS                                                         39.9±11.4                                                  45.3±10.6                            \<0.0001
   SF-36 MCS                                                         48.0±11.7                                                  53.6±9.5                             \<0.0001
   CAT score                                                          15.0±9.2                                                  10.5±7.7                             \<0.0001

Data are presented as % or mean±[sd]{.smallcaps}, unless otherwise stated. mMRC: modified Medical Research Council; SGRQ: St George\'s Respiratory Questionnaire; 6MWD: 6-min walking distance; SF-36: Medical Outcomes Study 36-item short-form questionnaire; PCS: physical component summary; MCS: mental component summary; CAT: Chronic Obstructive Pulmonary Disease Assesment Test.

Detailed analysis of respiratory medications is presented in [online supplementary table S2](http://openres.ersjournals.com/lookup/doi/10.1183/23120541.00069-2018.figures-only#fig-data-supplementary-materials). The low-income subjects report significantly more use of short-acting (37% *versus* 25%, p\<0.0001) and long-acting medications (25% *versus* 21%, p=0.003) than higher-income subjects, probably in response to higher rates of respiratory symptoms.

Socioeconomic status {#s3c}
--------------------

5-year follow-up phase 2 COPDGene visits were performed after implementation of the Affordable Care Act in the United States. In spite of that expansion of insurance coverage, 8% of low-income subjects lacked health insurance, compared to 2.4% of higher-income subjects ([table 3](#TB3){ref-type="table"}). Low-income subjects were less likely to receive preventive care and more likely to seek care in emergency rooms (12% *versus* 3%) than higher-income subjects. In addition, educational background differed significantly, with 45% of the low-income group reporting education beyond a high school diploma compared to 77% of the higher-income group. Subjects reported stretching medications and limiting physician visits because of costs and income ([table 4](#TB4){ref-type="table"}). Low-income subjects were twice as likely to not have gone to a doctor or not filled a prescription due to cost than higher income subjects. Low-income subjects used one or more cost-saving strategies significantly more often than higher-income subjects (25% *versus* 14%).

###### 

Socioeconomic factors beyond income

                                                **Low-income smokers (\<USD** **15** **000 per year)**   **Higher-income smokers (\>USD** **15** **000 per year)**   **p-value**
  -------------------------------------------- -------------------------------------------------------- ----------------------------------------------------------- -------------
  **Education beyond high school**                                        45                                                        77                                \<0.0001
  **Residence**                                                                                                                                                     
   Own home                                                               19                                                        70                                \<0.0001
   Rent                                                                   59                                                        22                                \<0.0001
   Lack a permanent home                                                  5                                                         0.5                               \<0.0001
  **Have health insurance**                                               90                                                        97                                \<0.0001
  **Access to preventative care**                                                                                                                                   
   Get preventative care from doctor/clinic                               88                                                        97                                \<0.0001
   Get preventative care from emergency room                              8                                                          1                                \<0.0001
   Do not get preventative care                                           4                                                          2                                \<0.0001
  **Lack a primary-care physician**                                       9                                                          3                                \<0.0001
  **Have access to internet**                                             55                                                        89                                \<0.0001
  **Exposures**                                                                                                                                                     
   Worked in a dusty job                                                  54                                                        40                                \<0.0001
   Worked in a fumes-related job                                          49                                                        45                                \<0.0001

Data are presented as %, unless otherwise stated.

###### 

Accommodation to healthcare costs

                                                                                                        **Low-income smokers (\<USD** **15** **000 per year)**   **Higher-income smokers (\>USD** **15** **000 per year)**   **p-value**
  ---------------------------------------------------------------------------------------------------- -------------------------------------------------------- ----------------------------------------------------------- -------------
  **In the last year, because of the expense or lack of coverage, have you ...**                                                                                                                                            
   Not gone to your doctor when you needed to                                                                                     11                                                         5                                \<0.0001
   Not filled a prescription                                                                                                      10                                                         6                                \<0.0001
   Stretched out a prescription medication by taking less of it or less often than it was prescribed                              9                                                          7                                  0.005
   Not gone to the hospital when you needed to                                                                                    6                                                          1                                \<0.0001
   Gone to an emergency room to be treated                                                                                        9                                                          2                                \<0.0001
   One or more of the above                                                                                                       25                                                        14                                \<0.0001

Data are presented as %, unless otherwise stated.

Baseline CT parameters {#s3d}
----------------------

Emphysema and wall area percentage at the baseline visit showed differences based on income group, with less emphysema (4.68±7.6% *versus* 6.24±8.9%, p\<0.0001) in the low-income group while airway wall thickness was greater (1.063±0.23 *versus* 1.018±0.21, p\<0.0001) in the low-income subjects ([table 1](#TB1){ref-type="table"}). Gas trapping was not significantly different at baseline. In multivariate linear regression models, income and educational level were highly significantly predictors of emphysema and segmental airway wall thickness at baseline, while education, but not income, was a significant factor for gas trapping ([table 5](#TB5){ref-type="table"}). Exposures to dust and fumes were tested separately in the baseline models and were not significant predictors of baseline emphysema or gas trapping, but dust exposure was a significant factor for airway wall thickness ([online supplementary tables](http://openres.ersjournals.com/lookup/doi/10.1183/23120541.00069-2018.figures-only#fig-data-supplementary-materials)) and income remained significant. Race was significant in all models, but after adjusting for income, African Americans had less emphysema, gas trapping and airway wall thickness. Although we adjusted for disease severity by FEV~1~ in the models, the distribution of African Americans by GOLD stage differed from non-Hispanic white subjects with less severe disease. African Americans had greater proportions in GOLD 0 and PRISm categories ([online supplementary figure S1](http://openres.ersjournals.com/lookup/doi/10.1183/23120541.00069-2018.figures-only#fig-data-supplementary-materials)).

###### 

Adjusted relationships of income to baseline computed tomography measures

                                         **Coefficient (95% CI)**     **p\>\|t\|**
  ------------------------------------ ----------------------------- --------------
  **Baseline emphysema**                     Model R^2^ 0.3287       
   Baseline FEV~1~                         −5.91 (−6.24-- −5.58)        \<0.0001
   Height                                    0.15 (0.11--0.18)          \<0.0001
   Current smoking                         −2.95 (−3.47-- −2.44)        \<0.0001
   Female                                  −4.16 (−4.80-- −3.53)        \<0.0001
   Age at recruitment                     −0.075 (−0.11-- −0.042)       \<0.0001
   Education beyond high school            −0.91 (−1.42-- −0.40)        \<0.0001
   Lower income                            −0.82 (−1.37-- −0.27)         0.004
   African American                        −2.21 (−2.81-- −1.61)        \<0.0001
   Smoking pack-years                      0.012 (0.0023--0.022)         0.015
  **Baseline gas trapping**                  Model R^2^ 0.4874       
   Baseline FEV~1~                       −14.67 (−15.30-- −14.03)       \<0.0001
   Height                                    0.39 (0.33--0.46)          \<0.0001
   Current smoking                         −3.92 (−4.93-- −2.92)        \<0.0001
   Female                                 −9.78 (−11.02-- −8.54)        \<0.0001
   Age at recruitment                       0.74 (0.011--0.14)           0.022
   Education beyond high school            −1.38 (−2.36-- −0.37)         0.007
   Lower income                             1.00 (−0.089--2.10)          0.072
   African American                        −5.19 (−6.40-- −3.99)        \<0.0001
   Smoking pack-years                      0.023 (0.0031--0.042)         0.023
  **Baseline airway wall thickness**         Model R^2^ 0.2928       
   Baseline FEV~1~                        −0.10 (−0.11-- −0.095)        \<0.0001
   Height                                 0.0036 (0.0027--0.0045)       \<0.0001
   Current smoking                         0.080 (0.066-- 0.094)        \<0.0001
   Female                                  −0.18 (−0.20-- −0.17)        \<0.0001
   Age at recruitment                   −0.0020 (−0.0028-- −0.0011)     \<0.0001
   Education beyond high school          −0.018 (−0.032-- −0.0048)       0.008
   Lower income                           0.021 (0.0062-- 0.036)         0.005
   African American                       −0.07 (−0.083-- −0.051)       \<0.0001
   Smoking pack-years                   0.00069 (0.00042--0.00095)      \<0.0001

FEV~1~: forced expiratory volume in 1 s.

Disease progression {#s3e}
-------------------

At the 5-year visit there were no significant differences in change in dyspnoea, quality of life by the SGRQ total score or 6MWD between low-income and higher income groups ([table 6](#TB6){ref-type="table"}). However, the low-income group showed greater progression in emphysema (0.68±3.7%) *versus* 0.06±3.95%, p\<0.0001), gas trapping (2.31±9.5% *versus* 0.62±8.2%, p\<0.0001) and FEV~1~ (−3.26±12.9% pred *versus* −1.40±10.1% pred, p\<0.0001). Change in airway wall thickness (−0.0061±0.137 *versus* −0.0025±0.108, p=0.409) was not significantly different.

###### 

Income status and 5-year change in spirometry, dyspnoea, health-related quality of life and imaging characteristics

                                                  **Low-income smokers (\<USD 15 000 per year)**   **Higher-income smokers (\>USD 15 000 per year)**   **p-value**
  ---------------------------------------------- ------------------------------------------------ --------------------------------------------------- -------------
  **FEV**~**1**~ **% pred**                                         −3.26±12.9                                        −1.40±10.1                        \<0.0001
  **FEV**~**1**~ **mL**                                             −225.6±342                                        −202.1±280                         0.0115
  **FEV**~**1**~ **mL per year**                                    −40.0±61.5                                        −35.9±50.0                         0.0142
  **Loss of \>300 mL in FEV**~**1**~ **n (%)**                     570 (36.8%)                                       1055 (32.19%)                        0.002
  **mMRC dyspnoea score^\#^**                                      0.0575±1.43                                        0.0649±1.14                         0.87
  **SGRQ total score**                                             0.0442±19.5                                        0.298±13.2                           0.6
  **Distance walked feet^¶^**                                        −130±401                                          −128±335                           0.82
  **Adjusted lung density^+^**                                      −1.90±12.1                                        −0.35±11.5                         0.0003
  **Emphysema^+^** **%**                                            0.677±3.74                                         0.06±3.95                        \<0.0001
  **Gas trapping^§^** **%**                                         2.31±9.52                                         0.623±8.17                        \<0.0001
  **Airway wall thickness mm**                                    −0.0061±0.137                                      −0.0025±0.108                        0.409
   Current smokers                                                   −0.0051                                            −0.017                            0.083
   Former smokers                                                    −0.0086                                            0.0051                           0.0291

Data are presented as mean±[sd]{.smallcaps}, unless otherwise stated. FEV~1~: forced expiratory volume in 1 s; mMRC: modified Medical Research Council; SGRQ: St George\'s Respiratory Questionnaire. ^\#^: n=1547 (low income), n=3271 (higher income); ^¶^: n=1503 (low income), n=3234 (higher income); ^+^: n=1085 (low income), n=2489 (higher income); ^§^: n=828 (low income), n=2133 (higher income).

Multivariate linear regression modelling for change outcomes (FEV~1~, emphysema, gas trapping and airway disease using airway wall thickness) with baseline level of the outcome, age, sex, race, smoking status, pack-years and FEV~1~ % pred ([table 7](#TB7){ref-type="table"}) showed that low income was a significant predictor of disease progression in models for FEV~1~ and airway wall thickness, but income was not a significant predictor of change in gas trapping or emphysema. Low income predicted worsening FEV~1~ and increased airway wall thickness.

###### 

Associations of income and education to disease progression

                                             **Coefficient (95% CI)**       **p-value**
  ------------------------------------- ---------------------------------- -------------
  **Change in FEV**~**1**~ **mL**               Model R^2^ 0.0660          
   Baseline FEV~1~ % pred                     −2.78 (−3.13-- −2.41)          \<0.0001
   Current smoking                           −51.36 (−70.99-- −31.73)        \<0.0001
   Female                                      68.47 (51.85--85.09)          \<0.0001
   Age at recruitment                          −0.39 (−1.54--0.77)             0.51
   Education beyond high school               −7.96 (−27.00--11.08)            0.41
   Low income                                −36.58 (−57.23-- −15.93)          0.001
   African American race                       49.21 (27.48--70.93)          \<0.0001
   Smoking pack-years                         −0.89 (−1.27-- −0.51)          \<0.0001
  **Change in emphysema**                       Model R^2^ 0.0925          
   Baseline emphysema                        −0.017 (−0.035--0.00073)          0.060
   Baseline FEV~1~ % pred                    −0.051 (−0.058-- −0.045)        \<0.0001
   Current smoking                              0.68 (0.39--0.98)            \<0.0001
   Female                                      −0.039 (−0.29--0.21)            0.76
   Age at recruitment                        −0.0057 (−0.023--0.011)           0.51
   Education beyond high school                0.21 (−0.075--0.49)             0.15
   Low income                                   0.14 (−0.17--0.45)             0.39
   African American race                       0.31 (−0.019--0.64)             0.065
   Smoking pack-years                        0.0051 (−0.00070--0.011)          0.085
  **Change in airway wall thickness**           Model R^2^ 0.1121          
   Baseline airway wall thickness             −0.20 (−0.22-- −0.18)          \<0.0001
   Baseline FEV~1~ % pred                −0.00018 (−0.00036-- −0.0000048)      0.044
   Current smoking                           0.0060 (−0.0029--0.015)           0.185
   Female                                    −0.022 (−0.030-- −0.014)        \<0.0001
   Age at recruitment                       0.00070 (0.00019--0.0012)          0.008
   Education beyond high school             −0.0013 (−0.0099--0.0073)          0.76
   Low income                                 0.013 (0.0036--0.022)            0.007
   African American race                    −0.015 (−0.025-- −0.0050)          0.003
   Smoking pack-years                      0.00013 (−0.000042--0.00031)        0.136

FEV~1~: forced expiratory volume in 1 s.

Discussion {#s4}
==========

Individuals with an annual income at or below the US minimum wage level had significantly greater impacts of smoking-related disease. Although the low-income group had less emphysema at baseline, they showed greater disease progression over 5 years in FEV~1~ and airway wall thickness. Current smoking was a clear factor predicting disease progression, but the effect of low income on disease progression remained after adjusting for current smoking. The adjusted difference in FEV~1~ between the low and higher income groups was 37 mL greater loss in the low-income group. This is a similar magnitude of effect to the adjusted impact of current smoking on FEV~1~ at 51 mL loss. These results suggest that low income is important and that factors other than continued smoking are involved in the relationship between low income and disease.

At baseline, low-income subjects had worse quality of life, worse dyspnoea, more chronic bronchitis and a shorter 6MWD, although smoking pack-years were not significantly different. Both current smoking and respiratory exacerbations requiring an emergency room visit or hospitalisation occurred twice as often in the low-income group relative to subjects reporting higher income. Our low-income group was similar in the distribution of disease severity to the higher-income subjects, but had more respiratory symptoms and had greater impairment in 6MWD, despite being significantly younger.

Factors that we considered to explain these results include that our low-income group reported less education, potentially impeding understanding of smoking risks; were less likely to have health insurance; and less likely to get preventative care from a doctor or clinic. In addition, they were more likely to have skipped medical visits or medications due to costs. Although they did report more respiratory exposures, the effect of those exposures on disease progression was not significant after adjusting for other factors. In addition, increased exposure to air pollution may play a role, but we do not have data available to assess that. Higher rates of respiratory medication use in the low-income group may be due to greater symptoms, or it may be the result of inadequate preventive and primary care.

Key social factors associated with low income and SES previously suggested to play a role in worse health include smoking, education, healthcare/insurance and unhealthy living conditions \[[@C17]\]. Smoking is much more prevalent in lower-income individuals \[[@C18]\] and C[hetty]{.smallcaps} *et al*. \[[@C1]\] found local geographic variation in mortality that was associated with smoking behaviour. In the C[hetty]{.smallcaps} *et al.* study, regional increased mortality linked to smoking behaviour was associated with heart disease and cancer, rather than increases in accidents, suicide or homicide. Others have identified associations between low SES and reduced lung function \[[@C6]\], increased hospitalisations \[[@C10]\] and increased mortality from respiratory disease \[[@C19]\]. In a systematic review, G[ershon]{.smallcaps} *et al*. \[[@C7]\] identified consistently negative effects of low SES on COPD symptoms, morbidity and mortality. In that meta-analysis, measures of SES included income, education and occupation. They found that individuals of the lowest SES were twice as likely to have poor outcomes as the higher-income group. Comparing studies across multiple diseases, they found that the negative impact of SES was greatest in COPD relative to diabetes, heart disease, stroke and cancer. Our findings are consistent with these published results and add detail about access to care and impact of low income on decision-making to seek care and comply with treatment.

Our low-income group had a greater proportion of African Americans, but we did not find worse disease at baseline or greater progression in these subjects; in fact, we found less after adjusting for income. The role of race in COPD risk and progression remains unclear, potentially because of the complexities of SES and genetic factors that may influence risk of disease. E[isner]{.smallcaps} *et al.* \[[@C6]\] in a study of insured health maintenance organisation subjects found that African Americans were not at increased risk of greater COPD severity after adjusting for demographics and physical characteristics. Our population varied in insurance status, but our results suggest that economics rather than race were the major factors predicting progression. African American subjects who experience exacerbations have worse quality of life than non-Hispanic white subjects with exacerbations \[[@C20]\], and they appear to have increased susceptibility to developing disease after smoking exposure \[[@C3]\], yet early work from the COPDGene study showed that African Americans had less emphysema than non-Hispanic white subjects adjusting for smoking pack-years, age and current smoking \[[@C4]\].

Education may influence decisions to continue smoking as well as interactions with the medical profession and compliance with treatment. A Norwegian study showed an association of lower educational level with greater emphysema but not airway wall thickness in COPD patients within a racially homogenous, rural population \[[@C21]\]. A previous COPDGene study relating parental COPD to risk of disease found that race was not significant, but education was an independent predictor of COPD \[[@C22]\]. Persistent smoking is associated with both lower income levels and lower educational attainments \[[@C18], [@C23]\]. Overall, the complex interplay of income, education, comorbidities and other factors increase the difficulty of defining solutions to continued smoking. The prominent role of continued smoking in low-income individuals suggests that strategies to improve outcomes must be linked to smoking cessation programmes. Smoking cessation programmes should be targeted to the needs and issues of low-income smokers.

Strengths of this study include the large cohort size, geographic diversity of the 21 clinical centres, extensive longitudinal clinical and radiographic data and the enhanced enrolment of African Americans. Limitations to generalisability include a US population that has unique and incomplete insurance coverage. Additionally, income level was documented at the phase 2 visit, not the initial visit when all of the other baseline variables were evaluated. While metrics of SES such as income and education have some stability over time \[[@C24]\], reverse causality cannot be excluded in this analysis. Those with faster disease progression may have been forced to retire, subsequently reducing their income from baseline to the reported level at the phase 2 visit. If they fell into the lowest category, this would bias the estimate of the difference between the low-income and the high-income group away from the null (overestimating the effect). However, the mean social security payment in the US is ∼USD 16 000 per year and retirement will not necessarily result in a drop into the lowest income category.

The information on income, education, comorbid disease, medication use and symptoms are all self-reported. Although verification of income and education would be ideal, it is uncommon to have that type of validation. Since subjects were offered the option to decline to answer these questions, we assume that responses are reflective of their social and economic situation. Although the lower comorbidity score in the low-income group may be accurate (possibly due to the lower average age), there may also be an ascertainment bias in that these subjects have reduced access to primary preventative care and may not have had an opportunity for physician diagnosis of asymptomatic conditions such as hypertension and high cholesterol. Additionally, while we have data on which medications subjects are prescribed, we do not have information on adherence, though our data on accommodations to healthcare costs suggest that low-income subjects may have lower adherence (more likely to not fill prescriptions, more likely to stretch out a prescription). Lower adherence rates may influence exacerbation rates and disease progression.

We chose to study the relationship of low income to a breadth of smokers both with and without spirometric COPD. Smoking impacts on the lung including emphysema, gas trapping and airway wall thickening are identified in smokers without obstruction \[[@C25]\]. We used CT metrics, reported symptoms and spirometry to provide a comprehensive analysis of baseline disease and progression.

The economic burden of smoking-related lung disease and COPD in the United States is sizeable, estimated to be USD 38.8 billion in 2005 \[[@C26]\]. As the third leading cause of death in the United States, there is value in improving outcomes of care for COPD. Worldwide, smoking and other respiratory exposures are common, and COPD is the fourth leading cause of death. Poverty and inadequate education are key issues to consider in order to reduce the burden of respiratory disease. Beyond smoking cessation, we identified a range of factors that could be addressed, including access to primary care and preventive care, access to health insurance and better information about health conditions. Although this study is based on data from the United States, similar associations of low SES to worse COPD have been identified in European cohorts, as well as around the world \[[@C7], [@C10], [@C21], [@C27]\]. Recognising and addressing the role of poverty in increased burden of disease, worse outcomes and more rapid disease progression represents an important strategy for all societies.
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